Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 27 resultados

STOOL4TB: Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with H... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2023-01 The COVID-19 pandemic had a devastating impact on tuberculosis (TB) control. In 2020, the number of people newly diagnosed with TB decreased...
2024-04-13 - 2025-12-31 | Financiado

PANGenS: Pan-Africa network for genomic surveillance of poverty related diseases and emerging pathogens FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM tramitó un HORIZON EUROPE: HORIZON-JU-GH-EDCTP3-2022-01 The main aim of the proposed project is to use genomic epidemiology of tuberculosis, malaria and emerging and re-emerging pathogens in Afric...
2023-07-01 - 2027-06-30 | Financiado

UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for...
2021-06-29 - 2028-05-31 | Financiado

MepAnti: Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti infecti... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-MSCA-ITN-2019 Anti-infective resistance is a serious global healthcare issue, calling for the development of compounds with a novel mode of action. An int...
2020-05-12 - 2024-09-30 | Financiado

DRTB-HDT: STRATIFIED HOST DIRECTED THERAPY FOR DRUG RESISTANT TUBERCULOSIS A RANDOMIZED CONTROLLED MULTI CENT... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-SC1-BHC-2018-2020 Tuberculosis is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring patients closely adher...
2019-12-19 - 2025-12-31 | Financiado

ERA4TB: EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms...
2019-12-12 - 2025-12-31 | Financiado

CORVOS: COmplement Regulation and Variations in Opportunistic infectionS FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-MSCA-ITN-2019 Opportunistic infections are defined as infections caused by pathogens primarily affecting immunocompromised subjects. Due to the immunodefi...
2019-09-04 - 2024-01-31 | Financiado

CARE: COMMON ACTION AGAINST HIV TB HCV ACROSS THE REGIONS OF EUROPE FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-SC1-BHC-2018-2020 CARE brings together distinguished scientists and highly representative networks in the European region, including Russia, in the fight agai...
2018-11-21 - 2021-06-30 | Financiado

anTBiotic: AnTBiotic progressing TB drug candidates to clinical proof of concept FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un H2020: H2020-SC1-2016-2017 Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been hig...
2016-12-02 - 2022-06-30 | Financiado

ENABLE: European Gram Negative Antibacterial Engine FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP6: The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
2014-02-01 - 2020-01-31 | Financiado

MEMBRANE DYNAMICS: The role of membrane trafficking in immune cell function FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM tramitó un FP7: Recently, receptor signal transduction has been identified to occur not only at the plasma membrane, but also at various intracellular compa...
Financiado

PIROVAC: Improvement of current and development of new vaccines for theileriosis and babesios of small rumina... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM tramitó un FP7: The proposal deals with the establishment of control measures for two major tick-borne diseases of small ruminants: theileriosis caused by T...
Financiado

PATHONGEN-TRACE: Next Generation Genome Based High Resolution Tracing of Pathogens FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM tramitó un FP7: "Next generation sequencing (NGS) has fundamentally altered genomic research. New developments will bring NGS costs and performance down to...
Financiado

EDENEXT: Biology and control of vector borne infections in Europe FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP7: To address the call for proposals 'Biology and control of vector-borne infections in Europe' launched by the European Commission, we want to...
Financiado

INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP7: Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
Financiado

CUREHLH: European initiative to improve knowledge treatment and survival of haemophagocytic syndromes in chi... FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP7: Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening inherited immune disorder of early childhood characterised by an un...
Financiado

TB PAN-NET: Pan European network for the study and clinical management of drug resistant tuberculosis FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP7: This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB)...
Financiado

THESCHISTOVAC: The targeted development of a new generation Vaccine for Schistosomiasis FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM participó en un FP7: The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or gly...
Financiado

FZB